



Prof Alessandro Aiuti

Alessandro Aiuti is Deputy Director, Clinical Research Coordinator, Head of Unit on Pathogenesis and Therapy of PID and Head of Pediatric Clinical Research Unit of SR-Tiget, Milan; Director of the Pediatric Immunohematology Unit, San Raffaele Hospital, Milan; full Professor of Pediatrics, and Director of the Residency Program of Pediatrics at Vita-Salute San Raffaele University, Milan, Italy.

He is M.D., Ph.D. in Molecular and Cell Biology. In 1998 he obtained the National Board in Hematology.

His main interests are hematology, immunology and pediatrics, particularly in the study of Primary Immunodeficiencies (PID). His main domains of research are: HSC gene therapy for genetic diseases (PI or co-PI of 5 clinical trials: ADA-SCID, WAS, β -thalassemia, MLD and MPS1), clonal dynamics of hematopoiesis, genetics and pathogenesis of primary immunodeficiencies.

He has published more than 230 papers in international peer reviewed journal including New England Journal of Medicine, Lancet, Science, Nature Medicine, Lancet Haematology, J Exp Med, Blood, JACI, Mol Ther., and 9 book chapters. Full list of his publications is available at <https://pubmed.ncbi.nlm.nih.gov/?term=aiuti+a&sort=date&size=50>.

He gave more than 200 lectures as invited speaker and abstract presentations to national and international congresses.

Prof. Aiuti has followed the entire development process of gene therapy for ADA-SCID (Strimvelis) from preclinical studies to clinical development, EU registration (2016) and market access. Strimvelis is currently licensed to Orchard Therapeutics.

Prof. Aiuti is member of the Board of the European Society of Gene and Cell Therapy (ESGCT), of the Inborn Errors Working Party (IEWP) Studies Committee of the European Society for Bone and Marrow Transplantation (EBMT), of the International Committee and of the Global Outreach Committee of American Society of Gene and Cell Therapy (ASGCT), and the Italian Working Group on Immunodeficiencies (IPINET). He is Co-chair of the Stem Cell and Gene Therapy WP of European Reference Network (ERN) on Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases Network (RITA).

Since 2019 he is Member (representing clinicians) of the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA).

He received several national and international awards for his scientific activity, including the Else Kroener Fresenius Price for Medical Research 2020 for groundbreaking successes in the development of gene therapies.

His research has been funded by international and national agencies, such as the European Union, Telethon Foundation, the Italian Ministry of Education, University and Research, the Italian Ministry of Health.

